Monday, 26 Jun 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
06 Apr 2017 Social Dr Jon Kay - a biomarker is a measured indicator of biologic/pathogenic processes or drug responses to a therapeutic intervention #CCFsummit
04 Apr 2017 Social FDA grants "breakthrough status" (expedited review) for Rituximab in Pemphigus Vulgaris based on recent Lancet study https://t.co/c7JpzzmvgM
04 Apr 2017 News Abatacept Use During Surgery
04 Apr 2017 Social FDAs Oncology Advisory Committee votes 11-0 approve subcut rituximab for lymphoma & CLL. Given in minutes not hours https://t.co/MoYk8KFkTV
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
09 Mar 2017 News European Biologic Manufacturers Issue Warnings About Biosimilar Switching
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS https://t.co/c1PW8aglhU
28 Feb 2017 Social Just like Oral Strategy Study (MTX+Tofa > Tofa) https://t.co/ReaHXaN5gK, DREAM registry shows TNFi + MTX > TNFi. https://t.co/2GiEfW1JJY
27 Feb 2017 News High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
23 Feb 2017 News Sirukumab Effective in Rheumatoid Arthritis
20 Feb 2017 News Abatacept Efficacy Giant Cell Arteritis
20 Feb 2017 Social Dr Mahadevan #RWCS17 ustekinumab has been approved for Crohns disease
17 Feb 2017 Social RT @DrRachelTate: No changes in safety, efficacy, or ab production in IFX vs inflectra. Eric Ruderman, MD & Arthur Kavanaugh, MD #rwcs2017…
17 Feb 2017 News Biosimilar Reports – February 2017
17 Feb 2017 Social Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by… https://t.co/un74cCDo04
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
17 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg https://t.co/aR0FWRzVHO
16 Feb 2017 News BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
16 Feb 2017 Social 100% of RA pts having all 3 factors(seropositivity; high IgG levels;detectable serum IL-33) will respond to Rituxan https://t.co/z6x1l5TgEa
15 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg https://t.co/aR0FWRzVHO